Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer

OBJECTIVES: CheckMate 227 (NCT02477826) evaluated first-line nivolumab-plus-ipilimumab versus chemotherapy in patients with metastatic nonsmall cell lung cancer (NSCLC) with programmed death ligand 1 (PD-L1) expression

• Reck, M.
• De, T.
• Paz-Ares, L.
• Edmondson-Jones, M.
• Yuan, Y.
• Yates, G.
• Zoffoli, R.
• Chaudhary, M. A.
• Lee, A.
• Varol, N.
• Penrod, J. R.